PHASE I-II TRIAL OF ADOPTIVE IMMUNOTHERAPY WITH HAPLOIDENTICAL KIR LIGAND-MISMATCHED NATURAL KILLER CELLS IN HIGH RISK ACUTE MYELOBLASTIC LEUKEMIA PATIENTS

被引：0
|
作者：
Curti, A. [1 ,2 ]
Ruggeri, L. [3 ]
D'Addio, A. [1 ,2 ]
Urbani, E. [3 ]
Bontadini, A. [4 ,5 ]
Fruet, F. [4 ,5 ]
Giudice, V [4 ,5 ]
Dan, E. [1 ,2 ]
Motta, M. R. [1 ,2 ]
Rizzi, S. [1 ,2 ]
Paolini, S. [1 ,2 ]
Martinelli, G. [1 ,2 ]
Velardi, A. [3 ]
Baccarani, M. [1 ,2 ]
Lemoli, R. M. [1 ,2 ]
机构：
[1] Univ Bologna, Dept Hematol & Oncol L&A Seragnoli, Inst Hematol & Med Oncol L&A Seragnoli, Bologna, Italy
[2] St Orsola Marcello Malpighi Hosp, Stem Cell Res Ctr, Bologna, Italy
[3] Univ Perugia, IRCCS Fdn Transplantat Biotechnol, Div Hematol & Clin Immunol, Dept Clin Med, Perugia, Italy
[4] St Orsola Marcello Malpighi Hosp, Immunohematol Serv, Bologna, Italy
[5] St Orsola Marcello Malpighi Hosp, Blood Bank, Bologna, Italy
来源：
HAEMATOLOGICA | 2008年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P225
引用
收藏
页码：S127 / S127
页数：1
相关论文
共 50 条
  • [41] Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality
    Ghayas C. Issa
    Hagop M. Kantarjian
    Lianchun Xiao
    Jing Ning
    Yesid Alvarado
    Gautam Borthakur
    Naval Daver
    Courtney D. DiNardo
    Elias Jabbour
    Prithviraj Bose
    Nitin Jain
    Tapan M. Kadia
    Kiran Naqvi
    Naveen Pemmaraju
    Koichi Takahashi
    Srdan Verstovsek
    Micheal Andreeff
    Steven M. Kornblau
    Zeev Estrov
    Alessandra Ferrajoli
    Guillermo Garcia-Manero
    Maro Ohanian
    William G. Wierda
    Farhad Ravandi
    Jorge E. Cortes
    Leukemia, 2020, 34 : 2914 - 2924
  • [42] Preliminary Results of a Phase 1/2 Clinical Trial of Cndo-109-Activated Allogeneic Natural Killer Cells in High Risk Acute Myelogenous Leukemia Patients in First Complete Remission
    Fehniger, Todd A.
    Stuart, Robert K.
    Cooley, Sarah A.
    Miller, Jeffrey S.
    Curtsinger, Julie
    Hillman, Timothy Mark
    Silver, Nova
    Szarek, Michael
    Lowdell, Mark W.
    Gorelik, Leonid
    Rowinsky, Eric
    BLOOD, 2014, 124 (21)
  • [43] Post-transplant immunotherapy with WT1-specific CTLs for high-risk acute myelogenous leukemia: a prospective clinical phase I/II trial
    Hee-Je Kim
    Hyun-Jung Sohn
    Jung-A Hong
    Hyun-Joo Lee
    Dae-Hee Sohn
    Chang-Ae Shin
    Hyun-Il Cho
    Woo-Sung Min
    Tai-Gyu Kim
    Bone Marrow Transplantation, 2019, 54 : 903 - 906
  • [44] Post-transplant immunotherapy with WT1-specific CTLs for high-risk acute myelogenous leukemia: a prospective clinical phase I/II trial
    Kim, Hee-Je
    Sohn, Hyun-Jung
    Hong, Jung-A
    Lee, Hyun-Joo
    Sohn, Dae-Hee
    Shin, Chang-Ae
    Cho, Hyun-Il
    Min, Woo-Sung
    Kim, Tai-Gyu
    BONE MARROW TRANSPLANTATION, 2019, 54 (06) : 903 - 906
  • [45] POST-TRANSPLANT IMMUNOTHERAPY WITH WT1-SPECIFIC CTLS FOR HIGH-RISK ACUTE MYELOGENOUS LEUKEMIA: A PROSPECTIVE CLINICAL PHASE I/II TRIAL
    Kim, H. J.
    Sohn, H. J.
    Hong, J. A.
    Lee, H. J.
    Sohn, D. H.
    Shin, C. A.
    Hyun, S. J.
    Hong, C. H.
    Choi, H.
    Shin, A. R.
    Cho, H. I.
    Min, W. S.
    Kim, T. G.
    HUMAN GENE THERAPY, 2018, 29 (11) : A8 - A8
  • [46] A phase I trial of adoptive transfer of allogeneic natural killer (NK) cells in patients (pts) with advanced non-small cell lung cancer (NSCLC)
    Iliopoulou, E. G.
    Kountourakis, P.
    Karamouzis, M. V.
    Doufexis, D.
    Ardavanis, A.
    Baxevanis, C. N.
    Rigatos, G.
    Papamichail, M.
    Perez, S. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [47] Ex vivo-expanded and activated haploidentical natural killer cells infusion before autologous stem cell transplantation in high-risk neuroblastoma: a phase I/II pilot study
    Tahereh Rostami
    Mohammad Ahmadvand
    Morteza Azari
    Amir Kasaeian
    Bahram Chahardouli
    Mohammad Reza Shemshadi Nia
    Mojtaba Azari
    Mohammad Reza Rostami
    Ramin Ahangar-Sirous
    Azadeh Kiumarsi
    Ghasem Janbabai
    Cancer Immunology, Immunotherapy, 74 (5)
  • [48] A Phase I-II Dose Escalation Trial of Clofarabine plus Melphalan and Thiotepa Followed by Unmodified Allogeneic Stem Cell Transplant (SCT) for the Treatment of High Risk or Advanced Acute Leukemia
    Boulad, Farid
    Kernan, Nancy A.
    Prockop, Susan E.
    Scaradavou, Andromachi
    Small, Trudy N.
    Klein, Elizabeth G.
    Barker, Juliet
    Jakubowski, Ann A.
    Koehne, Guenther
    Papadopoulos, Esperanza
    Perales, Miguel-Angel
    Young, James W.
    O'Reilly, Richard J.
    BLOOD, 2010, 116 (21) : 973 - 973
  • [49] Full haplotype-mismatched hematopoietic stem-cell transplantation: A phase II study in patients with acute leukemia at high risk of relapse
    Aversa, F
    Terenzi, A
    Tabilio, A
    Falzetti, F
    Carotti, A
    Ballanti, S
    Felicini, R
    Falcinelli, F
    Velardi, A
    Ruggeri, L
    Aloisi, T
    Saab, JP
    Santucci, A
    Perruccio, K
    Martelli, MP
    Mecucci, C
    Reisner, Y
    Martelli, MF
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (15) : 3447 - 3454
  • [50] Trials in Progress: A Phase I/II Clinical Trial of Off the Shelf Universal Donor Natural Killer Cells Combined with Chemotherapy for Treatment of Relapsed/Refractory Acute Myeloid Leukemia (KARMA)
    Lamb, Margaret
    Guinipero, Terri L.
    Lee, Dean Anthony
    BLOOD, 2023, 142
12345